Han et al., 2017 - Google Patents
Molecular chaperone HSP90 is necessary to prevent cellular senescence via lysosomal degradation of p14ARFHan et al., 2017
View HTML- Document ID
- 6660907670986604353
- Author
- Han S
- Ko A
- Kitano H
- Choi C
- Lee M
- Seo J
- Fukuoka J
- Kim S
- Hewitt S
- Chung J
- Song J
- Publication year
- Publication venue
- Cancer research
External Links
Snippet
The tumor suppressor function of p14ARF is regulated at a posttranslational level via mechanisms yet to be fully understood. Here, we report the identification of an unconventional p14ARF degradation pathway induced by the chaperone HSP90 in …
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
- C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Han et al. | Molecular chaperone HSP90 is necessary to prevent cellular senescence via lysosomal degradation of p14ARF | |
| Chaudhry et al. | GLI3 repressor determines Hedgehog pathway activation and is required for response to SMO antagonist glasdegib in AML | |
| Shen et al. | Novel small-molecule CX3CR1 antagonist impairs metastatic seeding and colonization of breast cancer cells | |
| Li et al. | YAP1-mediated CDK6 activation confers radiation resistance in esophageal cancer–Rationale for the combination of YAP1 and CDK4/6 inhibitors in esophageal cancer | |
| Siu et al. | p21-activated kinase 4 regulates ovarian cancer cell proliferation, migration, and invasion and contributes to poor prognosis in patients | |
| Hassanein et al. | Targeting SLC1a5‐mediated glutamine dependence in non‐small cell lung cancer | |
| Chen et al. | Hedgehog signaling regulates drug sensitivity by targeting ABC transporters ABCB1 and ABCG2 in epithelial ovarian cancer | |
| Pore et al. | Akt1 activation can augment hypoxia-inducible factor-1α expression by increasing protein translation through a mammalian target of rapamycin–independent pathway | |
| Yuan et al. | Deubiquitylase OTUD3 regulates PTEN stability and suppresses tumorigenesis | |
| Fenton et al. | Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240 | |
| Asangani et al. | Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer | |
| Scaglioni et al. | A CK2-dependent mechanism for degradation of the PML tumor suppressor | |
| Ducker et al. | Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors | |
| Cristiano et al. | A specific role for AKT3 in the genesis of ovarian cancer through modulation of G2-M phase transition | |
| Chen et al. | PD-L1 tumor-intrinsic signaling and its therapeutic implication in triple-negative breast cancer | |
| Caron et al. | Activated forms of H-RAS and K-RAS differentially regulate membrane association of PI3K, PDK-1, and AKT and the effect of therapeutic kinase inhibitors on cell survival | |
| Ye et al. | Targeting FBW7 as a strategy to overcome resistance to targeted therapy in non–small cell lung cancer | |
| Dai et al. | KEAP1-dependent synthetic lethality induced by AKT and TXNRD1 inhibitors in lung cancer | |
| Leventaki et al. | NPM-ALK oncogenic kinase promotes cell-cycle progression through activation of JNK/cJun signaling in anaplastic large-cell lymphoma | |
| Liu et al. | Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression | |
| Gopal et al. | Parthenolide promotes the ubiquitination of MDM2 and activates p53 cellular functions | |
| Ling et al. | FL118 induces p53-dependent senescence in colorectal cancer cells by promoting degradation of MdmX | |
| Jeannot et al. | The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase‐dependent mechanism | |
| Stella et al. | Suppression of survivin induced by a BCR-ABL/JAK2/STAT3 pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs | |
| Gao et al. | ErbB2 signaling increases androgen receptor expression in abiraterone-resistant prostate cancer |